Maria Staevska

Maria Staevska

Auto-generated profile, based on publicly available information

Maria Staevska

Department of Allergology, Medical University of Sofia, University Hospital Alexandrovska, Sofia, Bulgaria

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MSMaria Staevska
Maria Staevska
TPTodor Popov
Todor Popov
TKTanya Kralimarkova
Tanya Kralimarkova
CLCvetelina Lazarova
Cvetelina Lazarova
SKSteliana Kraeva
Steliana Kraeva
MCMartin K. Church
Martin K. Church

4 July 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
MRMarc A. Riedl
Marc A. Riedl
HFHenriette Farkas
Henriette Farkas
EAEmel Aygören-Pürsün
Emel Aygören-Pürsün
FPFotis Psarros
Fotis Psarros
DSDaniel F. Soteres
Daniel F. Soteres
DCDanny M. Cohn
Danny M. Cohn
Approved on-demand treatments for hereditary angioedema attacks need to be administered parenterally, a route of administration that is associated with delays in treatment or withholding of therapy. In this phase 3, double-blind, three-way crossover trial, we randomly assigned participants at least 12 years of age with type 1 or type 2 hereditary angioedema to take up to two oral doses of sebetralstat (300 mg or 600 mg) or placebo for an angioedema attack. The primary end point, assessed in a time-to-event analysis, was the beginning of symptom relief, defined as a rating of "a little better" on the Patient Global Impression of Change scale (ratings range from "much worse" to "much better") at two or more consecutive time points within 12 hours after the first administration of the trial agent. Key secondary end points, assessed in a time-to-event analysis, were a reduction in attack severity (an improved rating on the Patient Global Impression of Severity [PGI-S] scale, with ratings ranging from "none" to "very severe") at two or more consecutive time points within 12 hours and complete attack resolution (a rating of "none" on the PGI-S scale) within 24 hours. A total of 136 participants were assigned to one of six trial sequences, with 110 treating 264 attacks. The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P12), respectively. The time to reduction in the attack severity with the 300-mg dose and the 600-mg dose was faster than with placebo (P = 0.004 and P = 0.003), with median times of 9.27 hours (interquartile range, 1.53 to >12), 7.75 hours (2.19 to >12), and more than 12 hours (6.23 to >12). The time to complete resolution was faster with the 300-mg and 600-mg doses than with placebo (P = 0.002 and P<0.001). The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo. Sebetralstat and placebo had similar safety profiles; no serious adverse events related to the trial agents were reported. Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo. (Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, 2021-001226-21.).

1 March 2020 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
AGAnastasios E. Germenis
Anastasios E. Germenis
MMMaurizio Margaglione
Maurizio Margaglione
JPJoão Bosco Pesquero
João Bosco Pesquero
HFHenriette Farkas
Henriette Farkas
SCSven Cichon
Sven Cichon
BZBruce Zuraw
Bruce Zuraw

28 January 2014 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
MSM. Staevska
M. Staevska
MGM. Gugutkova
M. Gugutkova
CLC. Lazarova
C. Lazarova
TKT. Kralimarkova
T. Kralimarkova
VDVasil Dimitrov
Vasil Dimitrov
TPTodor Popov
Todor Popov
Background Many physicians believe that the most effective way to treat chronic urticaria is to take a nonsedating second‐generation H1‐antihistamine in the morning and a sedating first‐generation H1‐antihistamine, usually hydroxyzine, at night to enhance sleep. But is this belief well founded? Objectives To test this belief by comparing the effectiveness and prevalence of unwanted sedative effects when treating patients with chronic spontaneous urticaria (CSU) with levocetirizine 15 mg daily plus hydroxyzine 50 mg at night (levocetirizine plus hydroxyzine) vs. levocetirizine 20 mg daily (levocetirizine monotherapy). Methods In this randomized, double‐blind, cross‐over study, 24 patients with difficult‐to‐treat CSU took levocetirizine plus hydroxyzine or levocetirizine monotherapy for periods of 5 days each. At the end of each treatment period, assessments were made of quality of life (Chronic Urticaria Quality of Life Questionnaire, CU‐Q2oL), severity of urticaria symptoms (Urticaria Activity Score, UAS), sleep disturbance during the night and daytime somnolence. Results Both treatments significantly decreased UAS, night‐time sleep disturbances and CU‐Q2oL scores (P < 0·001) without significant differences between the two. Compared with baseline, daytime somnolence was significantly reduced by levocetirizine monotherapy (P = 0·006) but not by levocetirizine plus hydroxyzine (P = 0·218). Direct comparison of the two treatment modalities in terms of daytime somnolence favoured levocetirizine monotherapy (P = 0·026). Conclusions The widespread belief that sleep is aided by the addition of a sedating first‐generation H1‐antihistamine, usually hydroxyzine, at night is not supported. These results are in line with the urticaria guidelines, which state that first‐line treatment for urticaria should be new‐generation, nonsedating H1‐antihistamines only.

1 August 2018 in Gene
Verified
Journal Article
Closed access
GLGEDEON LOULES
GEDEON LOULES
MZMaria Zamanakou
Maria Zamanakou
FPFaidra Parsopoulou
Faidra Parsopoulou
SVSofia Vatsiou
Sofia Vatsiou
FPFotis Psarros
Fotis Psarros
AGAnastasios E. Germenis
Anastasios E. Germenis

1 May 2004 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
MSMaria T. Staevska
Maria T. Staevska
MMMariana A. Mandajieva
Mariana A. Mandajieva
VDVasil Dimitrov
Vasil Dimitrov